Comparing stress reduction methods to standard care for ovarian cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of a combination of propranolol, etodolac, mind-body resilience training, and music therapy in reducing physiological stress in patients undergoing primary debulking surgery for advanced ovarian cancer. Participants will be compared to a control group receiving standard care without these interventions. The study focuses on patients diagnosed with advanced-stage epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. The interventions are designed to be administered in the lead-up to surgery, allowing for assessment of their impact on stress levels during the perioperative period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Advanced (stage II-IV) epithelial ovarian, fallopian tube, or primary peritoneal carcinoma diagnosed on the basis of imaging, CA125, and clinical assessment
* Scheduled to undergo exploratory laparotomy and PDS or IDS
* Scheduled for surgery with at least 10 days of lead time, to allow the participant to take the β-blocker and COX2 inhibitor 7 days preoperatively
* Age ≥18 years
* ASA score of 1 to 3
* Ability to understand the study objectives and procedures, comply with the protocol, and provide informed consent

Exclusion Criteria:

* Chronic treatment with any β-blocker or COX inhibitor
* Contraindication for β-blocker therapy (asthma, second- or third-degree atrioventricular block, sinus bradycardia, sick sinus syndrome, right-sided heart failure, pheochromocytoma, peripheral vascular disease)
* Contraindication for COX2 inhibitor therapy (renal failure \[creatinine level \>1.5 mg/dL\], significant liver failure \[known cirrhosis, bilirubin level \>2\], active peptic disease), or current use of oral anticoagulant)
* Contraindication for regional epidural anesthesia
* Chronic autoimmune disease
* Active infection
* Pregnant
* Minimally invasive procedure
* Participation in another clinical trial that interferes with this study

Where it's running

• Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
  Basking Ridge, New Jersey, United States Recruiting
• Memorial Sloan Kettering Monmouth (Limited protocol activities)
  Middletown, New Jersey, United States Recruiting
• Memorial Sloan Kettering Bergen (Limited Protocol Activities)
  Montvale, New Jersey, United States Recruiting
• Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities)
  Commack, New York, United States Recruiting
• Memorial Sloan Kettering Westchester (Limited Protocol Activities)
  Harrison, New York, United States Recruiting
• Memorial Sloan Kettering Cancer Center (All Protocol Activities)
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Kara Long Roche, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Kara Long Roche, MD
• Email: longrock@mskcc.org
• Phone: 212-639-7043

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• IMNN-001 combined with standard chemotherapy for newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer

  This trial tests whether adding IMNN-001 (an intraperitoneal IL-12 plasmid therapy) to standard paclitaxel/carboplatin chemotherapy helps people with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting at 10 sites Phase 3 Imunon · Orlando, Florida and 9 other locations · NCT06915025

• Heated chemotherapy followed by Niraparib for advanced ovarian cancer

  This study is testing if a heated chemotherapy treatment followed by a drug called Niraparib can help people with advanced ovarian cancer do better after surgery compared to regular chemotherapy.

  Recruiting at 59 sites Phase 3 GOG Foundation · Duarte, California and 58 other locations · NCT05659381

• Personalized timing for interval debulking surgery in advanced ovarian cancer

  This study will test whether timing interval debulking surgery based on the CA125 drop (KELIM) after neoadjuvant chemotherapy helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer have better surgical outcomes than usual care.

  Recruiting Phase 2 The University of Hong Kong · Guangzhou and 5 other locations · NCT07023484

• Testing PHST001 for advanced solid tumors

  This study is testing a new treatment called PHST001 to see if it is safe and effective for people with advanced solid tumors that haven't responded to other therapies.

  Recruiting at 20 sites Phase 1 Pheast Therapeutics · Beverly Hills, California and 19 other locations · NCT06840886

• Immune cell therapy for recurrent ovarian cancer

  This study is testing a new immune cell therapy called 27T51 to see if it can help women with recurrent ovarian cancer feel better and fight their disease.

  Recruiting at 5 sites Phase 1 Regeneron Pharmaceuticals · Boston, Massachusetts and 4 other locations · NCT06469281

• Using blood volume management during surgery for ovarian cancer patients

  This study tests if a blood management technique called acute normovolemic hemodilution can help women with advanced ovarian cancer during surgery by reducing the need for blood transfusions and improving safety.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06290193

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.